Abstract
Over-the-counter (OTC) statin availability has been hypothesized to represent a strategy for treating consumers at moderate risk of coronary heart disease (CHD) who are currently not receiving drug therapy. The viability of this strategy has been questioned, particularly with respect to the public health benefit that can be obtained in an unsupervised treatment environment. The previously reported Consumer Use Study of Over-the-Counter Lovastatin (CUSTOM) examined consumer behavior in a simulated OTC setting in which 20 mg lovastatin could be purchased. Framingham CHD risk scores were calculated for 981 self-selected consumers who used OTC lovastatin in CUSTOM. Overall, this group had a median 10-year CHD risk of 10%, but with significant numbers of consumers with estimated risks of <5% and >20%. According to the risk profile of CUSTOM consumers, the use of 20 mg lovastatin for 10 years would be expected to prevent approximately 33,100 CHD events per 1 million users. This represents a 10-year number needed to treat of 30 consumers. This optimal benefit may be reduced because some higher risk consumers in CUSTOM used lovastatin rather than appropriate, more aggressive supervised care. On the basis of the frequencies of diversion...Continue Reading
References
Jan 1, 1991·Archives of Internal Medicine·R H BradfordD P Hurley
Oct 3, 1996·The New England Journal of Medicine·F M SacksE Braunwald
Jun 5, 1998·JAMA : the Journal of the American Medical Association·J R DownsA M Gotto
Jun 13, 1998·Archives of Internal Medicine·P McBrideR L Brown
Sep 17, 1998·Circulation·J P FrolkisP S Suhan
Jun 20, 2000·The American Journal of Cardiology·S C Smith
Jun 20, 2000·The American Journal of Cardiology·A M Gotto
May 23, 2001·JAMA : the Journal of the American Medical Association·UNKNOWN Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Apr 23, 2003·Circulation·Jacques Genest, Terje R Pedersen
Jul 14, 2004·Circulation·Scott M GrundyUNKNOWN American Heart Association
Sep 11, 2004·Journal of the American College of Cardiology·Scott M GrundyUNKNOWN Coordinating Committee of the National Cholesterol Education Program
Nov 3, 2004·Journal of the American College of Cardiology·Michael J KorenUNKNOWN ALLIANCE Investigators
Nov 3, 2004·The American Journal of Cardiology·Eric P Brass
Nov 3, 2004·The American Journal of Cardiology·David B Nash, Stephen A Nash
Nov 16, 2004·The American Journal of Cardiology·Jeffrey M MelinJohn D Irvin
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Jun 9, 2005·Annals of Internal Medicine·Niteesh K Choudhry, Jerry Avorn
Nov 3, 2005·Nature Clinical Practice. Cardiovascular Medicine·Jonathan Abrams
Citations
Jun 21, 2008·The New England Journal of Medicine·Mary E Tinetti
Mar 11, 2008·The Journal of Clinical Hypertension·Thomas G Pickering
Aug 28, 2007·The American Journal of Cardiology·Valentin Fuster
May 13, 2008·The American Journal of Cardiology·Eric P BrassJeffrey G Levine
Feb 27, 2009·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·UNKNOWN American Society of Health-System Pharmacists
Nov 4, 2011·Clinical Pharmacology and Therapeutics·E P BrassO Renn
Jan 9, 2007·The American Journal of Clinical Nutrition·Maret G Traber